Teleflex Incorporated (NYSE:TFX) – Analysts at William Blair boosted their FY2017 EPS estimates for shares of Teleflex in a research note issued on Thursday. William Blair analyst B. Weinstein now expects that the medical technology company will post earnings per share of $8.26 for the year, up from their previous estimate of $8.12. William Blair also issued estimates for Teleflex’s FY2018 earnings at $9.55 EPS.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 3rd. The medical technology company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.13. The business had revenue of $528.60 million for the quarter, compared to analysts’ expectations of $518.98 million. Teleflex had a return on equity of 16.12% and a net margin of 12.36%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period last year, the firm posted $1.89 earnings per share.

ILLEGAL ACTIVITY WARNING: “Teleflex Incorporated Forecasted to Post FY2017 Earnings of $8.26 Per Share (NYSE:TFX)” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/07/teleflex-incorporated-forecasted-to-post-fy2017-earnings-of-8-26-per-share-nysetfx.html.

TFX has been the topic of several other research reports. Barclays PLC reiterated a “buy” rating on shares of Teleflex in a research note on Monday, June 26th. Needham & Company LLC reiterated a “buy” rating on shares of Teleflex in a research note on Friday. Zacks Investment Research upgraded Teleflex from a “hold” rating to a “buy” rating and set a $228.00 price target on the stock in a research note on Friday, June 23rd. Deutsche Bank AG boosted their price target on Teleflex from $213.00 to $220.00 and gave the company a “buy” rating in a research note on Monday, May 8th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $230.00 price target on shares of Teleflex in a research note on Thursday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $221.17.

Teleflex (NYSE TFX) opened at 214.26 on Monday. The stock has a market capitalization of $9.64 billion, a PE ratio of 44.47 and a beta of 1.05. Teleflex has a 12 month low of $136.53 and a 12 month high of $217.97. The firm has a 50-day moving average price of $207.61 and a 200 day moving average price of $195.00.

Hedge funds have recently modified their holdings of the company. UBS Asset Management Americas Inc. increased its stake in shares of Teleflex by 118.9% in the fourth quarter. UBS Asset Management Americas Inc. now owns 72,560 shares of the medical technology company’s stock worth $11,692,000 after buying an additional 39,419 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Teleflex by 4.8% in the fourth quarter. Teachers Advisors LLC now owns 45,560 shares of the medical technology company’s stock worth $7,342,000 after buying an additional 2,074 shares in the last quarter. Creative Planning increased its position in shares of Teleflex by 3.7% in the first quarter. Creative Planning now owns 2,259 shares of the medical technology company’s stock worth $438,000 after buying an additional 81 shares in the last quarter. Pennsylvania Trust Co increased its position in shares of Teleflex by 0.7% in the first quarter. Pennsylvania Trust Co now owns 2,165 shares of the medical technology company’s stock worth $419,000 after buying an additional 15 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in shares of Teleflex during the first quarter worth about $349,000. Hedge funds and other institutional investors own 92.95% of the company’s stock.

In other news, VP John Deren sold 2,246 shares of the company’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $194.07, for a total value of $435,881.22. Following the sale, the vice president now owns 3,989 shares in the company, valued at $774,145.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen K. M.D. Klasko sold 200 shares of the company’s stock in a transaction dated Tuesday, August 1st. The stock was sold at an average price of $208.41, for a total value of $41,682.00. Following the completion of the sale, the director now owns 8,080 shares in the company, valued at approximately $1,683,952.80. The disclosure for this sale can be found here. Insiders sold 10,546 shares of company stock worth $2,079,856 in the last 90 days. Company insiders own 2.39% of the company’s stock.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Tuesday, August 15th will be paid a $0.34 dividend. The ex-dividend date is Friday, August 11th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.63%. Teleflex’s payout ratio is 26.00%.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.